ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 2 for:    ustekinumab, lupus
Previous Study | Return to List | Next Study

A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT02349061
Recruitment Status : Active, not recruiting
First Posted : January 28, 2015
Results First Posted : June 12, 2018
Last Update Posted : November 2, 2018
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

January 23, 2015
January 28, 2015
May 15, 2018
June 12, 2018
November 2, 2018
October 15, 2015
May 15, 2017   (Final data collection date for primary outcome measure)
Percentage of Participants With a Systemic Lupus Erythematosus Responder Index (SRI-4) Composite Response (CR) at Week 24 [ Time Frame: Week 24 ]
SRI-4 response was defined as greater than or equal to 4-point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score, no new British Isles Lupus Assessment Group (BILAG) A and no more than 1 new BILAG B domain score and no worsening (less than 10 percent increase) from baseline in Physician's Global Assessment of Disease Activity (PGA). Composite response is defined as SRI-4 response in participants who do not meet treatment failure criteria. SLEDAI-2K assessment consists of 24 items with total score of 0 to 105, with higher scores representing increased disease activity. BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 9 organ systems. For each organ system: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale = from very well (0)-very poor (10).
Percentage of Participants With a Composite SRI-4 Response at Week 24 [ Time Frame: Week 24 ]
Systemic Lupus Erythematosus Responder index (SRI-4) is defined as greater than or equal to (>=) 4 point reduction in Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score, no new domain scores in either British Isles Lupus Assessment Group (BILAG) A or B and no worsening (less than [˂] 10 millimeters [mm] increase) from baseline in the Physician's Global Assessment of Disease Activity (PGA). The SLEDAI - 2k assessment consists of 24 items which has total score of 0 to 105, with higher scores representing increased disease activity. The BILAG Index: assessing clinical signs, symptoms, or laboratory parameters related to SLE, divided into 8 organ systems. For each organ system, letter score was given: A=severe disease, B=moderate disease, C=mild stable disease, D=inactive, but previously active, E=inactive and never affected. The PGA assess disease activity on a visual analogue scale (VAS) = from 'very well' (0) to 'very poor' (10).
Complete list of historical versions of study NCT02349061 on ClinicalTrials.gov Archive Site
Not Provided
  • Change From Baseline in SLEDAI-2K Score at Week 24 [ Time Frame: Week 24 ]
    Systemic lupus erythematosus disease activity index 2000 (SLEDAI - 2k) assessment consists of 24 items. A weighted score of 8, 4, 2, and 1 were assigned for items 1 to 8, items 9 to 14, items 15 to 21, and items 22 to 24, respectively. A SLEDAI global score for Systemic lupus erythematosus (SLE) disease activity was derived by adding all weighted scores. Total possible score range for SLEDAI - 2K global score is 0 to 105, with higher scores representing increased disease activity.
  • Change From Baseline in Physician Global Assessment of Disease Activity (PGA) at Week 24 [ Time Frame: Week 24 ]
    The Physician Global Assessment of Disease Activity will be recorded on a visual analogue scale (VAS = 0 to 10 centimeters [cm]). The scale for the assessments range from 'no lupus activity' (0) to 'extremely active lupus' (10).
  • Percentage of Participants With BICLA Response at Week 24 [ Time Frame: Week 24 ]
    The BILAG-based Combined Lupus Assessment (BICLA) requires participants to meet response criteria across 3 assessment tools and no treatment failure must be recorded: 1) BILAG improvement classified as: a) All BILAG A scores at baseline improved to either BILAG B, C or D b) All BILAG B scores at baseline improved to either BILAG C or D, c) No worsening in disease activity defined as no new BILAG A scores and <= 1 new BILAG B score. 2) No worsening of total SLEDAI-2K from baseline (change <= 0). 3) No significant deterioration (<10 mm increase) in 100 mm visual analogue PGA scale.
Not Provided
Not Provided
 
A Phase 2a, Efficacy and Safety Study of Ustekinumab in Systemic Lupus Erythematosus
A Multicenter, Randomized, Double-blind, Placebo-controlled, Proof-of-Concept Study of Ustekinumab in Subjects With Active Systemic Lupus Erythematosus
The purpose of this study is to evaluate the efficacy of ustekinumab as measured by a reduction in disease activity for subjects with active Active Systemic Lupus Erythematosus (SLE - chronic disorder of connective tissue in which there can be skin rash, arthritis, kidney problems, and anemia, among other problems).
A multicenter (more than one medical research center involved in study), randomized (study drug assigned by chance), double-blind (neither the Investigator nor the participant know about the study drug), placebo-controlled, proof-of-concept study of ustekinumab in participants with active systemic lupus erythematosus. Participants will be screened to achieve all inclusion criteria and none exclusion criteria and will then receive either ustekinumab or placebo along with concomitant background medicine. Participants will be primarily assessed for response using the Systemic Lupus Erythematosus Response Index 2000 (SRI-4). Participants' safety will be assessed throughout the study.
Interventional
Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Lupus Erythematosus, Systemic
  • Drug: Ustekinumab IV
    Weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0.
    Other Name: STELARA
  • Drug: Placebo Infusion
    Placebo intravenously at Week 0.
  • Drug: Placebo SC
    Placebo subcutaneously at Weeks 8 and 16.
  • Drug: Ustekinumab SC
    Ustekinumab 90 mg subcutaneously every 8 weeks up to Week 40 and up to Week 104 in study extension (for eligible participants)
  • Other: Concomitant Medication
    Concomitant treatment (mycophenolate, azathioprine/6-mercaptopurine, methotrexate, hydroxychloroquine and/or chloroquine, oral corticosteroids, NSAIDs, antihypertensive medications, and topical medications) through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48.
  • Experimental: Ustekinumab plus Concomitant Medication
    Participants will receive weight-range based dosing of approximately 6 mg/kg of ustekinumab intravenously at Week 0 followed by ustekinumab 90 mg subcutaneously (SC) every 8 weeks (q8w) up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
    Interventions:
    • Drug: Ustekinumab IV
    • Drug: Ustekinumab SC
    • Other: Concomitant Medication
  • Experimental: Placebo followed by Ustekinumab plus Concomitant Medication
    Participants will receive placebo intravenously at Week 0 followed by placebo subcutaneously at Weeks 8 and 16. At week 24 participants will receive ustekinumab SC q8w up to Week 40. Participants who meet the study extension inclusion criteria will continue to receive ustekinumab 90 mg SC q8w starting at Week 48 or 56 through Week 104. Participants will continue stable concomitant treatment through Week 48, as well as through the study extension although tapering of corticosteroids is encouraged beyond Week 48. Participants who complete or discontinue study treatment will be evaluated for 16 additional Weeks of safety follow-up.
    Interventions:
    • Drug: Placebo Infusion
    • Drug: Placebo SC
    • Drug: Ustekinumab SC
    • Other: Concomitant Medication
van Vollenhoven RF, Hahn BH, Tsokos GC, Wagner CL, Lipsky P, Touma Z, Werth VP, Gordon RM, Zhou B, Hsu B, Chevrier M, Triebel M, Jordan JL, Rose S. Efficacy and safety of ustekinumab, an IL-12 and IL-23 inhibitor, in patients with active systemic lupus erythematosus: results of a multicentre, double-blind, phase 2, randomised, controlled study. Lancet. 2018 Oct 13;392(10155):1330-1339. doi: 10.1016/S0140-6736(18)32167-6. Epub 2018 Sep 21.

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
102
100
March 21, 2019
May 15, 2017   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Subjects must have documented medical history to meet SLICC classification criteria for SLE for a minimum of 3 months prior to first dose
  • At least 1 well-documented (subject file, referring physician letter, or laboratory result), unequivocally positive, documented test for autoantibodies in medical history including either of the following: ANA, and/or anti-dsDNA antibodies, and/or anti-Smith antibodies
  • At least 1 unequivocally positive autoantibody test including ANA and/or anti-dsDNA antibodies and/or anti-Smith antibodies detected during screening
  • At least 1 BILAG A and/or 2 BILAG B domain scores observed during screening prior to first administration of study agent
  • Demonstrate active disease based on SLEDAI-2K score greater than or equal to (>=) 6 observed during screening and assessed approximately 2 to 6 weeks prior to randomization. Must also have SLEDAI-2K score >= 4 for clinical features (ie, SLEDAI excluding laboratory results) at Week 0 prior to the first administration of study agent

Exclusion Criteria:

  • Have other inflammatory diseases that might confound the evaluations of efficacy, including but not limited to rheumatoid arthritis (RA), psoriatic arthritis (PsA), RA/lupus overlap, psoriasis or active Lyme disease
  • Are pregnant, nursing, or planning a pregnancy or fathering a child while enrolled in the study or within 4 months after receiving the last administration of study agent
  • Have received systemic or topical cream/ointment preparations of cyclosporine A or other systemic immunomodulatory agents other than those described in inclusion criteria within the past 3 months prior to first administration of study agent
  • Have received a single B cell targeting agent within 3 months prior to first study agent administration; or received more than 1 previous B cell targeting therapy including belimumab or epratuzamab within 6 months prior to first administration of the study agent; or received B cell depleting therapy (eg, rituximab) within 12 months prior to first administration of the study agent or have evidence of continued B-cell depletion following such therapy
  • Have ever received ustekinumab
  • Participant has a history of malignancy within 5 years before screening (exceptions are squamous and basal cell carcinomas of the skin that has been treated with no evidence of recurrence for at least 3 months before the first study agent administration and carcinoma in situ of the cervix that has been surgically cured)
Sexes Eligible for Study: All
18 Years to 75 Years   (Adult, Older Adult)
No
Contact information is only displayed when the study is recruiting subjects
Argentina,   Australia,   Germany,   Hungary,   Mexico,   Poland,   Spain,   Taiwan,   United States
United Kingdom
 
NCT02349061
CR106661
CNTO1275SLE2001 ( Other Identifier: Janssen Research & Development, LLC )
2014-005000-19 ( EudraCT Number )
Yes
Studies a U.S. FDA-regulated Device Product: No
Not Provided
Janssen Research & Development, LLC
Janssen Research & Development, LLC
Not Provided
Study Director: Janssen Research & Development, LLC Clinical Trial Janssen Research & Development, LLC
Janssen Research & Development, LLC
October 2018

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP